{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:04:06Z","timestamp":1773155046527,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:00:00Z","timestamp":1611446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:00:00Z","timestamp":1611446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40199-020-00386-1","type":"journal-article","created":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T03:02:47Z","timestamp":1611457367000},"page":"211-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bosentan-induced immune hemolytic anemia in 17\u00a0years old man. A case report"],"prefix":"10.1007","volume":"29","author":[{"given":"Fatemeh","family":"Afra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjan","family":"Mehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9264-0248","authenticated-orcid":false,"given":"Soha","family":"Namazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,24]]},"reference":[{"key":"386_CR1","doi-asserted-by":"crossref","first-page":"19.088","DOI":"10.7812\/TPP\/19.088","volume":"24","author":"S Kumar","year":"2020","unstructured":"Kumar S, Bansal R, Bansal P, et al. Ceftriaxone-induced hemolytic Anemia: a rare case report. Perm J. 2020;24:19.088.","journal-title":"Perm J"},{"key":"386_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1182\/asheducation-2009.1.73","volume":"1","author":"G Garratty","year":"2009","unstructured":"Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2009;1:73\u20139.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"386_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/ejh.13187","volume":"102","author":"GE Tanios","year":"2019","unstructured":"Tanios GE, Doley PB, Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol. 2019;102:157\u201362.","journal-title":"Eur J Haematol"},{"key":"386_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1365-2141.2011.08784.x","volume":"154","author":"E Garbe","year":"2011","unstructured":"Garbe E, Andersohn F, Bronder E, Klimpel A, Thomae M, Schrezenmeier H, et al. Drug induced immune haemolytic anaemia in the Berlin case-control surveillance study. Br J Haematol. 2011;154:644\u201353.","journal-title":"Br J Haematol"},{"key":"386_CR5","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMcp1900554","volume":"381","author":"RA Brodsky","year":"2019","unstructured":"Brodsky RA. Warm autoimmune hemolytic Anemia. N Engl J Med. 2019;381:647\u201354.","journal-title":"N Engl J Med"},{"key":"386_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/00003246-198706000-00001","volume":"15","author":"WM Stahl","year":"1987","unstructured":"Stahl WM. Acute phase protein response to tissue injury. Crit Care Med. 1987;15:545\u201350.","journal-title":"Crit Care Med"},{"key":"386_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.7326\/0003-4819-39-3-619","volume":"39","author":"I Snapper","year":"1953","unstructured":"Snapper I, Marks D, Schwartz L, et al. Hemolytic anemia secondary to Mesantoin. Ann Intern Med. 1953;39:619\u201323.","journal-title":"Ann Intern Med"},{"issue":"3","key":"386_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.chest.2018.11.030","volume":"155","author":"JR Klinger","year":"2019","unstructured":"Klinger JR, Elliott CG, Levine DJ, Bossone E, Duvall L, Fagan K, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest. 2019;155(3):565\u201386.","journal-title":"Chest."},{"key":"386_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"386_CR10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1503\/cmaj.171315","volume":"190","author":"M Elissa","year":"2018","unstructured":"Elissa M, et al. Diagnosing and managing drug allergy. CMAJ. 2018;190:532\u20138.","journal-title":"CMAJ."},{"key":"386_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2147\/VHRM.S4713","volume":"5","author":"C Valerio","year":"2009","unstructured":"Valerio C. Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag. 2009;5:607\u201319.","journal-title":"Vasc Health Risk Manag"},{"key":"386_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1365-2141.2010.08097.x","volume":"149","author":"RJ Barst","year":"2010","unstructured":"Barst RJ, Mubarak KK, Machado RF, Ataga KI, Benza RL, Castro O, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol. 2010;149:426\u201335.","journal-title":"Br J Haematol"},{"key":"386_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809\u201318.","journal-title":"N Engl J Med"},{"key":"386_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1183\/09031936.00138706","volume":"30","author":"M Humbert","year":"2007","unstructured":"Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007;30:338\u201344.","journal-title":"Eur Respir J"},{"key":"386_CR15","first-page":"887","volume":"3","author":"E Gabbay","year":"2007","unstructured":"Gabbay E, Fraser J, McNeil K. Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag. 2007;3:887\u2013900.","journal-title":"Vasc Health Risk Manag"},{"key":"386_CR16","volume-title":"Product Mmonograph PrMYLAN-BOSENTAN","author":"Mylan Pharmaceuticals ULC","year":"2016","unstructured":"Mylan Pharmaceuticals ULC. Product Mmonograph PrMYLAN-BOSENTAN. 2016."},{"key":"386_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.blre.2010.06.004","volume":"24","author":"G Garratty","year":"2010","unstructured":"Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24:143\u201350.","journal-title":"Blood Rev"},{"key":"386_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40264-013-0023-0","volume":"36","author":"R Meyboom","year":"2013","unstructured":"Meyboom R. Intentional Rechallenge and the clinical Management of Drug-Related Problems. Drug Saf. 2013;36:163\u20135.","journal-title":"Drug Saf"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-020-00386-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-020-00386-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-020-00386-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T02:18:49Z","timestamp":1670897929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-020-00386-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,24]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["386"],"URL":"https:\/\/doi.org\/10.1007\/s40199-020-00386-1","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,24]]},"assertion":[{"value":"10 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author(s) declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}